

credit any overpayment to Deposit Account No. 06-1300 (Our Order 68126-1/RFT/RMS/RMK).

Please amend the above-identified application as follows:

In the Specification:

Please replace the paragraph on page 66 beginning at line 5 with the following rewritten paragraph:

C<sup>2</sup>  
The designed EPOR analog is linked by a GGGGS (SEQ ID NO:35) linker sequence to a PDA designed coiled-coil sequence (RMEKLEQKV/KELLRKNERLEEEVERLKQLVGER (SEQ ID NO:31), based on the GCN4 structure. For example: 1ebp\_d12\_GCN4 (SEQ ID NO: 37; see also Example 3) is composed of 1ebp\_d12 (SEQ ID NO:6) (1ebp\_d1 (SEQ ID NO:4) add 1ebp\_d2 (SEQ ID NO:5) mutants together), plus GGGGS (SEQ ID NO:35), plus designed GCN4 sequence.

In the Sequence Listing:

Please replace page 1 of the paper copy of the "Sequence Listing" with the enclosed substitute sheet for page 1.

Please replace page 34 of the paper copy of the "Sequence Listing" with the enclosed substitute sheet for page 34 and new page 35.

In the Claims:

Please cancel claims 1-19

Please add the following new claims:

C<sup>2</sup>  
~~20.~~ An erythropoietin receptor (EPOR) analog protein comprising an amino acid sequence that has at least one amino acid substitution as compared to the wild-type EPOR sequence, wherein said substitutions are selected from amino acids residues comprising one or more of the following regions: